46 recruiting, 39 active not recruiting, 8 not yet recruiting, 4 terminated. 98 Phase 2, 18 Phase 1, 7 Phase 3.
Follow Echocardiography Test: new trials by email Literature Review of Echocardiography Test trials Research Report on Echocardiography Test
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma Biospecimen Collection, Echocardiography Test, Fluorouracil - Childhood Posterior Fossa Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 70 | 2026-12-11 | 2026-09-30 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2026-10-01 | 2026-08-27 |
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 23 | 2026-10-01 | 2026-08-20 |
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2026-09-28 | 2026-10-30 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-29 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma Archive Sample Retrieval, Biospecimen Collection, Chest Radiography - Glioblastoma, IDH-Wildtype | Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-08-28 | 2026-10-26 |
| Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 31 | 2026-08-28 | 2026-10-23 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-30 |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 37 | 2026-06-17 | 2026-09-04 |
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-05-27 | 2026-10-06 |
Showing 20 of 98. Sign in to see all of them.
Leukemia, Myeloid, Acute (18) · Lymphoma (8) · Myelodysplastic Syndromes (8) · Burkitt Lymphoma (7) · Leukemia, Biphenotypic, Acute (7) · Lung Neoplasms (6) · Multiple Myeloma (6) · Lymphoma, Large B-Cell, Diffuse (5) · Melanoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Fallopian Tube Neoplasms (4) · Neoplasm Metastasis (4) · Ovarian Neoplasms (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Carcinoma, Renal Cell (3)
National Cancer Institute (NCI) (62) · Fred Hutchinson Cancer Center (10) · Children's Oncology Group (6) · Mayo Clinic (4) · City of Hope Medical Center (3) · University of Washington (3) · AIDS Malignancy Consortium (1) · Asrar Alahmadi (1) · Emory University (1) · Joal Beane (1) · Joshua Palmer (1) · NRG Oncology (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1)
United States (92) · Puerto Rico (15) · Canada (14) · Australia (6) · Guam (2) · New Zealand (2)
A P Chen (2) · Amer M Zeidan (2) · Joyce F Liu (2) · Aarti Bhatia (1) · Adam J Esbenshade (1) · Alain P Algazi (1) · Alan L Ho (1) · Alexander N Shoushtari (1) · Alexandre V. Hirayama, MD (1) · Andrea B Apolo (1) · Andreas N Saltos (1) · Anjali S Advani (1) · Ann Dahlberg (1) · Anne S Tsao (1)
PMID 23810467, PMID 25218906, PMID 26586415, PMID 31969335, PMID 32463741, PMID 33020646, PMID 33048619, PMID 33362722, PMID 33394722, PMID 33882143, PMID 34380663, PMID 34416167, PMID 34686472, PMID 34716198, PMID 35031545, PMID 35133871, PMID 35138919, PMID 35613998, PMID 36322825, PMID 36351402, PMID 36521030, PMID 36902217, PMID 37053535, PMID 37185961, PMID 37322121, PMID 37934000, PMID 38127487, PMID 38243705, PMID 38358334, PMID 38433347, PMID 38591867, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39666929, PMID 39693587, PMID 39856213, PMID 39913886, PMID 39928953, PMID 40402690, PMID 40588371, PMID 40685312, PMID 40721981, PMID 40802906, PMID 40865033, PMID 40902132, PMID 41066729, PMID 41213241, PMID 41672597
U10CA180820 (15), U10CA180886 (10), U10CA180821 (8), U10CA180888 (8), U10CA180868 (7), UM1CA186689 (6), UM1CA186709 (4), P30CA033572 (3), UM1CA186644 (3), UM1CA186688 (3), UM1CA186691 (3), UM1CA186704 (3), UM1CA228823 (3), ZIABC011078 (3), N01CM00071 (2)